Literature DB >> 10471091

Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells.

P Gomes1, P Soares-da-Silva.   

Abstract

The present study aimed to determine the kinetics of L-3,4-dihydroxyphenylalanine (L-DOPA) uptake in an immortalised cell line of rat capillary cerebral endothelial cells (clones RBE 4 and RBE 4B), to define the type of interaction with 3-O-methyl-L-DOPA (3-OM-L-DOPA), sensitivity to 2-aminobicyclo(2,2,1)-heptane-2-carboxylic acid (BHC), N-(methylamino)-isobutyric acid (MeAIB) and sodium. Non-linear analysis of the saturation curves for L-DOPA and 3-OM-L-DOPA revealed in RBE 4 cells Km values (in microM) of 72 (53, 91) and 40 (25, 57) and in RBE 4B cells Km values (in microM) of 60 (46, 74) and 44 (13, 75), respectively. IC50 values for 3-OM-L-DOPA (RBE 4, 642 [542, 759] microM; RBE 4B, 482 [475, 489] microM) obtained in the presence of a nearly saturating (250 microM) concentration of L-DOPA were greater than the corresponding Ki values (RBE 4, 143 [121, 170] microM; RBE 4B, 93 [92, 95] microM) obtained in the presence of a nearly saturating (250 microM) concentration of 3-OM-L-DOPA; this is compatible with a competitive type of interaction between L-DOPA and 3-OM-L-DOPA. Uptake of both L-DOPA and 3-OM-L-DOPA in RBE 4 and RBE 4B cells was sensitive to BHC with similar IC50 values. MeAIB (up to 2.5 mM) was found not to interfere with the uptake of both L-DOPA and 3-OM-L-DOPA. Uptake of (250 microM) L-DOPA and 3-OM-L-DOPA in the absence of sodium in the incubation medium was similar to that observed in the presence of increasing concentrations of sodium (20-140 mM). Homogenates of both cell lines were endowed with considerable COMT activity. Incubation of RBE 4 and RBE 4B cells with L-DOPA (25 microM) in the presence of a methyl donor (S-adenosyl-L-methionine) resulted in the formation of 3-OM-L-DOPA; this was abolished by 1 microM tolcapone. The fractional outflow of intracellular L-DOPA through the luminal and abluminal cell side was not affected by the presence of intracellular 3-OM-L-DOPA. The fractional outflow of exogenous 3-OM-L-DOPA applied from the luminal cell border was similar to that observed for 3-OM-L-DOPA with origin in L-DOPA. It is concluded that RBE 4 and RBE 4B cells are endowed with the L-type amino acid transporter through which L-DOPA and 3-OM-L-DOPA can be taken up, and 3-OM-L-DOPA behaves as a competitive inhibitor for the uptake of L-DOPA. This, however, only occurs for luminal cell inward movement but not for abluminal cell outward movement of the substrates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471091     DOI: 10.1016/s0028-3908(99)00042-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.

Authors:  Lauri Peura; Kalle Malmioja; Kristiina Huttunen; Jukka Leppänen; Miia Hämäläinen; Markus M Forsberg; Mikko Gynther; Jarkko Rautio; Krista Laine
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

2.  Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Authors:  José-Francisco Rocha; Amílcar Falcão; Ana Santos; Roberto Pinto; Nelson Lopes; Teresa Nunes; Lyndon C Wright; Manuel Vaz-da-Silva; Patrício Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2014-06-14       Impact factor: 2.953

3.  Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.

Authors:  José-Francisco Rocha; Éric Sicard; Nicolas Fauchoux; Amílcar Falcão; Ana Santos; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Teresa Nunes; Luís Almeida; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2016-12-02       Impact factor: 4.335

4.  The role of 3-O-methyldopa in the side effects of L-dopa.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Jennifer King; Clivel Charlton
Journal:  Neurochem Res       Date:  2007-08-24       Impact factor: 3.996

5.  Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.

Authors:  Pedro Silveira; Manuel Vaz-da-Silva; Luis Almeida; Joana Maia; Amilcar Falcão; Ana Loureiro; Leonel Torrão; Rita Machado; Lyndon Wright; Patrício Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2003-09-27       Impact factor: 2.953

6.  Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Authors:  Luis Almeida; José Francisco Rocha; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

7.  Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Authors:  José Francisco Rocha; Luis Almeida; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 8.  Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Authors:  Nuno Borges
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.

Authors:  Joe Yamamoto; Tomohiro Omura; Sachiko Kasamo; Shota Yamamoto; Masayoshi Kawata; Atsushi Yonezawa; Yosuke Taruno; Hisako Endo; Hitoshi Aizawa; Nobukatsu Sawamoto; Kazuo Matsubara; Ryosuke Takahashi; Yoshikazu Tasaki
Journal:  J Neural Transm (Vienna)       Date:  2020-11-02       Impact factor: 3.575

10.  Modified carbon nanotube paste electrode for voltammetric determination of carbidopa, folic Acid, and tryptophan.

Authors:  Sakineh Esfandiari Baghbamidi; Hadi Beitollahi; Hassan Karimi-Maleh; Somayeh Soltani-Nejad; Vahhab Soltani-Nejad; Sara Roodsaz
Journal:  J Anal Methods Chem       Date:  2012-05-15       Impact factor: 2.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.